UK eyes FDA if no EMA deal
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
If the UK fails to secure full regulatory alignment with the European Union (EU) on medicines as part of negotiations over its ‘Brexit’ withdrawal from the EU, then the country may seek to align with the USFood and Drug Administration (FDA),according to a UK House of Commons health and social care committee report on the impact of Brexit on medicines.